AMI Research, a division of Hawk Associates, announced this morning that it has updated its stock valuation report of NeoGenomics, Inc. (OTCBB: NGNM) based on the company’s first quarter results. The complete 16-page report is available at http://www.amistockreports.com/NGNM_Q109Update.html.
NeoGenomics specializes in cancer genetics, flow cytometry and molecular diagnostic testing. Headquartered in Fort Myers, FL, the company has laboratories in Nashville, TN, Irvine, CA and Fort Myers and provides diagnostic tests to pathologists, oncologists, urologists, and hospitals throughout the United States.
In summary, the AMI Research report stated, “We like management’s focus on long term sustainable value creation rather than short term profitability. We believe NeoGenomics has an excellent foundation in place to begin with the next phase of rapid development. We maintain our strong buy rating and our long term target price range of $2.08 to $2.38 per share.”
Let us hear your thoughts below: